Annovis Bio Inc. (ANVS) News
Filter ANVS News Items
ANVS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANVS News Highlights
- For ANVS, its 30 day story count is now at 3.
- Over the past 16 days, the trend for ANVS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ANVS are BIO, DEC and DRUG.
Latest ANVS News From Around the Web
Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
These Stocks under $10 Are Poised To ExplodeIn this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […] |
Annovis Bio to Participate in the 139th Yale CEO SummitBERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to participate in the 139th Yale CEO Summit in New York on December 11-12, 2023. The Yale CEO Summit is a bi-annual event; it brings together influential CEOs from major US Fortune 500 companies for informal ye |
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s DiseaseBERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024. "We are pleased to share the completion of our Parkinson's study which marks a significant step forward in our ongoing mission t |
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's WhyAnnovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease. |
Annovis Bio Appoints Andrew Walsh as Vice President FinanceBERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer’s and Parkinson’s clinical trials in 2024. The addition of Andrew Walsh to our |
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original ProjectionsBERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that AD phase II/III study of its lead compound buntanetap has exceeded full enrollment. Since the initiation of phase II/III study in March 2023, over 700 patients were screened and a total of 353 patients enrolled across 54 sit |
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateBERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial results for the period ended September 30, 2023, and reviewed recent accomplishments. Third Quarter 2023 Highlights and New Developments Clinical Updates AD phase II/III study Status of Phase II/III Alzheim |
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s PatientsBERWYN, Pa., November 02, 2023--Recent developments in biomarker research have enabled the performance of measurements of important biomarkers in plasma rather than in CSF (cerebrospinal fluid), making it possible to follow the changes in biomarkers during the course of a neurodegenerative disease while reducing patients’ burden. |
Annovis Bio Announces Pricing of $7.5 Million Public OfferingBERWYN, Pa., October 31, 2023--Annovis Bio, Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced the pricing of an underwritten public offering of 1,250,000 units consisting of (i) one share of its common stock and (ii) an accompanying warrant (each warrant to purchase one share of common stock). The combined offering price to the p |
Annovis Bio Announces Launch of Proposed Public OfferingBERWYN, Pa., October 30, 2023--Annovis Bio, Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) an accompanying warrant to purchase shares of common stock. The shares of common stock and the accompanying warrant wil |